Literature DB >> 7869193

Precocious puberty in children with neurofibromatosis type 1.

R Habiby1, B Silverman, R Listernick, J Charrow.   

Abstract

We undertook a comprehensive study of children with neurofibromatosis type 1 (NF-1) cared for in a large multidisciplinary clinic to determine the prevalence of precocious puberty and its relationship to optic pathway tumors (OPTs). Precocious puberty was diagnosed in 7 of 219 children with NF-1 (5 boys and 2 girls) examined between Jan. 1, 1985, and April 20, 1993. All seven children had OPTs involving the optic chiasm; they represented 39% of children with NF-1 and chiasmal tumors (95% confidence interval, 17% to 64%). Eleven prepubertal children (aged 2 to 10 years) with NF-1 and OPTs, and age- and sex-matched NF-1 control subjects without OPTs, underwent luteinizing hormone-releasing hormone (LH-RH) stimulation tests. Two boys with OPTs had pubertal luteinizing hormone (LH) responses, and testosterone levels > 10 ng/dl. Basal LH levels were also elevated in these two boys when tested with a very sensitive immunochemiluminometric assay. None of the children without an OPT had either a pubertal response to LH-RH or an elevated basal LH level. We conclude that precocious puberty in children with NF-1 is found exclusively in those who have OPTs involving the optic chiasm; it is a common complication in those children. With the use of a highly sensitive LH assay, biochemical evidence of hypothalamic-pituitary-gonadal axis activation may be demonstrated, even without provocative testing.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7869193     DOI: 10.1016/s0022-3476(95)70449-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  22 in total

Review 1.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

Review 2.  Neoplasms associated with germline and somatic NF1 gene mutations.

Authors:  Sachin Patil; Ronald S Chamberlain
Journal:  Oncologist       Date:  2012-01-12

3.  Precocious puberty: An experience from a major teaching hospital in Central Saudi Arabia.

Authors:  Huda A Osman; Nasir A M Al-Jurayyan; Amir M I Babiker; Hessah M N Al-Otaibi; Reem D H AlKhalifah; Sharifah D A Al Issa; Sarar Mohamed
Journal:  Sudan J Paediatr       Date:  2017

4.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

Review 5.  Delayed and Precocious Puberty: Genetic Underpinnings and Treatments.

Authors:  Anisha Gohil; Erica A Eugster
Journal:  Endocrinol Metab Clin North Am       Date:  2020-12       Impact factor: 4.741

6.  Familial male-limited precocious puberty in neurofibromatosis type I.

Authors:  Yvonne Yijuan Lim; Raymond Ming-En Chan; Kah Yin Loke; Cindy Weili Ho; Yung Seng Lee
Journal:  Eur J Pediatr       Date:  2013-08-28       Impact factor: 3.183

7.  The impact of coexisting genetic mutations on murine optic glioma biology.

Authors:  Aparna Kaul; Joseph A Toonen; Scott M Gianino; David H Gutmann
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

Review 8.  Advances in the treatment of neurofibromatosis-associated tumours.

Authors:  Andrew L Lin; David H Gutmann
Journal:  Nat Rev Clin Oncol       Date:  2013-08-13       Impact factor: 66.675

Review 9.  Optic Pathway Gliomas in Neurofibromatosis Type 1.

Authors:  Cynthia J Campen; David H Gutmann
Journal:  J Child Neurol       Date:  2018-01       Impact factor: 1.987

10.  Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma.

Authors:  Balazs Hegedus; Frank W Hughes; Joel R Garbow; Scott Gianino; Debasish Banerjee; Keunyoung Kim; Mark H Ellisman; Milam A Brantley; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2009-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.